medigraphic.com
ISSN 2078-7162 (Print)

2020, Number 3

<< Back Next >>

Rev Cub de Med Fis y Rehab 2020; 12 (3)

About a case of multiple sclerosis and multiple myeloma

Rodríguez BY, Prado AKI, Díaz MCE

Language: Spanish
References: 16
Page:
PDF size: 455.32 Kb.


ABSTRACT

Multiple sclerosis is considered the most common chronic demyelinating neurological disease of the central nervous system in young adults. It limits the patient's personal, family or social activity. Multiple myeloma is the most frequent of the monoclonal gammopathies. It is a malignant disease with neoplastic proliferation of a clone of plasma cells, which produce abnormal amounts of a homogeneous type of immunoglobulin. The objective of the article is to expose a rare case of concomitant autoimmune diseases. Unlike multiple sclerosis, multiple myeloma appears more frequently from the age of 40 on wards and in the male sex. Both diseases share an unknown origin, influence the cells and the function of the immune system. It is concluded that the success in the diagnosis and control of disabling diseases lies in not overlooking any sign or symptom that the patient refers to.


REFERENCES

  1. Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vecsei L, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006 [acceso: 18/08/2018]; (13):700-22. Disponible en: https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1468-1331.2006.01342.x

  2. Mendibe MM, Boyero S, Rodrigo RM, Zarranz JJ. Esclerosis Múltiple. En: Zarranz JJ y cols, editor. Neurología. 5ta ed. Barcelona, España: Elsevier; 2013, p. 45-62.

  3. Koch HN, Sorensen PS. The changing demography pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010 [acceso: 18/08/2018]; (9):520-32. Disponible en: https://www.clinicalkey.es

  4. Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008 [acceso: 18/08/2018]; 71(2):129-35. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109189/

  5. Compston A, Confavreux Ch, Lassmann H, McDonald I, Miller D, Noseworthy J, et al. Multiple sclerosis. Philadelphia: Churchill Livingstone, Elsevier; 2006: 208-306.

  6. Charil A, Filippi M. Inflammatory demyelination and neurodegeneration in early multiple sclerosis. J. Neurol Sci. 2007 [acceso: 18/08/2018]; 259(1-2): 7-15. Disponible en: Disponible https://www.clinicalkey.es

  7. Trapp BD, Rasohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurology disability. Current Opinion Neurology. 1999 [acceso: 22/08/2018]; 12(3):295-302. Disponible en: https://journals.lww.com/co-neurology/Fulltext/1999/06000/Axonal_pathology_in_multiple_sclerosis_.8.aspx

  8. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodríguez M. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000 [acceso: 18/08/2018]; (47):707-17. Disponible en: https://onlinelibrary.wiley.com/doi/epdf/10.1002/1531

  9. Déniz A, Alemany M, Marrero I. Evaluación y tratamiento de la espasticidad en la esclerosis múltiple. En: Javier Juan F, editor. Evaluación y tratamiento de la espasticidad. Madrid: Panamericana; 2009. p. 169-84.

  10. García MA. Consenso para el tratamiento de la esclerosis múltiple. Rev Esp Neurol. 2017 [acceso: 18/08/2018]; 32(2):113-9 Disponible en: https://www.elsevier.es/es-revista-neurologia-295-articulo-consenso-el-tratamiento-esclerosis-multiple-S0213485316300299

  11. Villa AM. Nuevas terapias en esclerosis múltiple y sus desafíos. Rev Neurol Arg. 2011 [acceso: 02/03/2018]; 3(3):149-50. Disponible en: https://www.elsevier.es/es-revista-neurologia-argentina-301-articulo-nuevas-terapias-esclerosis-multiple-sus-S1853002811000164?referer=buscador

  12. Pozuelo MB, Benito LJ. Terapia con Vitamina D en la Esclerosis Múltiple. Rev Esp Esclerosis Múltiple [Internet]. 2013 [acceso: 02/03/2018]; (28):5-9. Disponible en: http://revistaesclerosis.es/pdf/partes/v5_28dic13_01.pdf

  13. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: Revisions to McDonald criteria. Ann Neurol. 2011 [acceso: 02/03/2018]; 69(2):292-302. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084507

  14. Merck & Co. Mieloma múltiple. En: El Manual Merck de diagnóstico y tratamiento. Beers MH, editor. 11ma ed. Barcelona, España: Elsevier; 2007. p. 1230-3.

  15. Bártulos IM, Marzo Sola ME, Etrella Ruiz LA, Bravo Anguiano Y. Estudio epidemiológico de la esclerosis múltiple en La Rioja. Neurología. 2015 [acceso: 02/03/2018]; 30 (9):552-60. Disponible en: https://reader.elsevier.com/reader/sd/pii/

  16. Armas MR. Mieloma múltiple. En: Medicina Interna Basada en la Evidencia. Santiago de Chile: Empendium. 2015 [acceso: 02/03/2018]; Disponible en: https://empendium.com/manualmibe/chapter/B34.II.15.15




2020     |     www.medigraphic.com